KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Cash from Financing Activities for 11 consecutive years, with $116.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 589.82% to $116.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $426.0 million through Dec 2025, up 28.33% year-over-year, with the annual reading at $426.0 million for FY2025, 28.33% up from the prior year.
  • Cash from Financing Activities hit $116.4 million in Q4 2025 for CRISPR Therapeutics AG, down from $296.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $305.9 million in Q1 2024 to a low of -$466000.0 in Q2 2024.
  • Historically, Cash from Financing Activities has averaged $55.5 million across 5 years, with a median of $10.5 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 19863.87% in 2021 and later plummeted 102.78% in 2024.
  • Year by year, Cash from Financing Activities stood at $6.3 million in 2021, then tumbled by 60.66% to $2.5 million in 2022, then skyrocketed by 1471.39% to $38.9 million in 2023, then tumbled by 56.66% to $16.9 million in 2024, then soared by 589.82% to $116.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CRSP at $116.4 million in Q4 2025, $296.8 million in Q3 2025, and $2.3 million in Q2 2025.